ArticleFrontiers in bioengineering and biotechnology2023
Endogenous CRISPR/Cas systems for genome engineering in the acetogens
Article in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Transferable genetic toolsets for nonmodel gut Clostridia enable in vivo reversible control of metabolite production.Nature biotechnology · 2026Article
- A characterized promoter suite enables metabolic rewiring of the acetogen Acetobacterium woodii toward ethanol production.Biotechnology for biofuels and bioproducts · 2026Article
- Improving autotrophic D-lactate production by heterologous expression of a pyruvate formate lyase in an LDHD-expressing Acetobacterium woodii strain.Applied microbiology and biotechnology · 2026Article
- Target discrimination and PAM profiling of the Thermotoga maritima type I-B CRISPR system.The Biochemical journal · 2026Article
- New Insights into CRISPR-like Arrays inPathogens (Basel, Switzerland) · 2026Article
- Careful CO Addition Enhances Autotrophic d-Lactate Formation With EngineeredEngineering in life sciences · 2026Article
- Hi-TARGET: a fast, efficient and versatile CRISPR type I-B genome editing tool for the thermophilic acetogen Thermoanaerobacter kivui.Biotechnology for biofuels and bioproducts · 2025Article
- Inducible promoters of bacterial microcompartments improve the CRISPR/Cas9 tools for efficient metabolic engineering ofApplied and environmental microbiology · 2025Article
- Refining and illuminating acetogenic Eubacterium strains for reclassification and metabolic engineering.Microbial cell factories · 2024Article
- Engineered acetogenic bacteria as microbial cell factory for diversified biochemicals.Frontiers in bioengineering and biotechnology · 2024Review
- Article
- Heterologous Production of Isopropanol Using Metabolically EngineeredBioengineering (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acetogenic bacteria can play a major role in achieving Net Zero through their ability to convert CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.